Key Findings
- Curcumin significantly reduced WOMAC pain scores with a large effect size (SMD = -0.93, 95% CI: -1.21 to -0.65, p < 0.001) across osteoarthritis trials
- Physical function (WOMAC function subscale) improved significantly (SMD = -0.85, p < 0.001) and stiffness scores also decreased meaningfully in curcumin groups vs placebo
- In head-to-head comparisons, curcumin 1500mg/day was non-inferior to ibuprofen 1200mg/day for knee OA pain over 4 weeks, with significantly fewer GI adverse events (13% vs 38%)
- Curcumin reduced serum CRP by a weighted mean of 2.3 mg/L and IL-6 by 1.6 pg/mL compared to placebo, confirming its systemic anti-inflammatory mechanism in arthritis patients
- Enhanced bioavailability formulations (Meriva phospholipid complex, BCM-95, Theracurmin) showed significantly larger effect sizes than standard curcumin powder, underscoring the importance of formulation choice